Compare Newmont Corporation (NEM) vs Nuwellis Inc (NUWE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Newmont Corporation vs Nuwellis Inc — how do they compare? Newmont Corporation trades at $118.25 (market cap $121.75B), while Nuwellis Inc trades at $0.69 (market cap $2.20M). The key difference: Newmont Corporation is far larger — about 55340.9× Nuwellis Inc's market cap, and Newmont Corporation pays a 0.9% dividend while Nuwellis Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Newmont Corporation for 58 Days and Nuwellis Inc for 26 Days on average.
| NEM | NUWE | |
|---|---|---|
Market Cap | $121.75B | $2.20M |
Volume | 5,421,125 | 121,544 |
Sector | Basic Materials | Health |
52-Week High | $135.14 | $146.65 |
52-Week Low | $78.63 | $0.68 |
Typical Hold Time | 58 Days | 26 Days |
Enterprise Value | $118.34B | -$1.52M |
Dividend Yield | 0.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Newmont Corporation (NEM) trades at $113.54, down 2.45% over 24 hours, with technical indicators showing a bearish short-term trend. The company reported strong fundamentals, including record free cash flow of $5.3 billion in H1 2026 (Defense World, 2026-10-01) and consistent earnings beats in recent quarters. Revenue grew to $22.67 billion in 2025, with net income margin improving to 31.25%. Analyst sentiment remains positive, with a consensus price target of $136.83 and 76% buy ratings.
The outlook for NEM is supported by robust cash flow generation and operational improvements, but near-term price pressure exists from technical bearish signals and gold price volatility. Investment appeal lies in its valuation metrics, such as a P/E of 14.57, and shareholder returns via dividends. Key risks include sensitivity to gold prices and execution of growth projects. The stock offers value for long-term investors despite current market weakness.
NUWE trades at $0.6907, down 1.48% on the day, with a bearish technical signal from moving averages despite oversold RSI readings. The company reported revenue growth to $9M in 2026 but remains deeply unprofitable with a net income margin of -125.63%. Recent news highlights console sales growth and strategic expansions in pediatric and critical care markets.
The outlook is high-risk due to persistent losses and negative cash flow, though analyst sentiment is split with a 50% buy rating. Investment potential hinges on the company's ability to achieve profitability and scale its Aquadex platform, while risks include cash burn and competitive pressures in the medical device sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Newmont Corporation
Newmont Corp is primarily a gold producer with operations and/or assets in the United States, Canada, Mexico, Dominican Republic, Peru, Suriname, Argentina, Chile, Australia, and Ghana. It is also engaged in the production of copper, silver, lead and zinc. The company's operations are organized in five geographic regions: North America, South America, Australia, Africa and Nevada.
Read more on NEM →About Nuwellis Inc
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →
